Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis
Submitted by susan on Sat, 2008-04-05 14:27
Peak incidence of rotavirus gastroenteritis is seen in infants between 6 and 24 months of age. The researchers therefore aimed to assess the 2-year efficacy and safety of an oral live attenuated human rotavirus vaccine for prevention of severe gastroenteritis in infants.
Main Topic:
Mark Content Private(Internal):
External URL:
Main Type:
dtelocal
Email Alert:
1181
9619
371
Publication Date:
05/04/2008